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MicroRNAs (miRNAs) are key regulators of gene expression, playing important roles in development, homeostasis,
and disease. Recent experimental evidence indicates that mutation or deregulation of the MIR17HG gene (miR-17 ~
92 cluster) contributes to the pathogenesis of a variety of human diseases, including cancer and congenital
developmental defects. We report on a 9-year-old boy who presented with developmental delay, autism spectrum
disorder, short stature, mild macrocephaly, lower facial weakness, hypertelorism, downward slanting palpebral
fissures, brachydactyly, and clinodactyly. SNP-microarray analysis revealed 516 kb microduplication at 13q31.3
involving the entire MIR17HG gene encoding the miR-17 ~ 92 polycistronic miRNA cluster, and the first five exons of
the GPC5 gene. Family study confirmed that the microduplication was maternally inherited by the proband and
one of his five half-brothers; digit and other skeletal anomalies were exclusive to the family members harboring the
microduplication.
This case represents the smallest reported microduplication to date at 13q31.3 and provides evidence supporting
the important role of miR-17 ~ 92 gene dosage in normal growth and skeletal development. We postulate that any
dosage abnormality of MIR17HG, either deletion or duplication, is sufficient to interrupt skeletal developmental
pathway, with variable outcome from growth retardation to overgrowth.
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MicroRNAs (miRNAs) are single-stranded small mole-
cules of approximately 22 to 24 nucleotides that are fre-
quently expressed in clusters. They play an important
role in the post-transcriptional control of gene expres-
sion by binding to complementary sites within target
mRNAs, thereby mediating their degradation or repres-
sing translation [1-3]. MIR17HG, the host gene for the
miR-17 ~ 92 cluster, encodes for six individual miRNAs:
MIR17, MIR18A, MIR19A, MIR20A, MIR19B1 and
MIR92A1. The miR-17 ~ 92 miRNA cluster is located
on human chromosome 13q31.3, in a genomic region
that is frequently amplified in lymphomas and other
cancers. The mature miRNAs encoded by this locus are* Correspondence: morteza.x.hemmat@questdiagnostics.com
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unless otherwise stated.expressed in high amounts in cancer cells [4,5]. This
cluster and its paralogues have important roles in can-
cers because of their ability to repress expression of
many tumor-associated proteins [6-14]. Overexpression
promotes cell proliferation and reduces apoptosis by
regulating cell cycle progression [15-17].
The miR-17 ~ 92 cluster also plays an important role in
normal growth and skeletal development. Transcription
of this cluster is activated by both MYC (C-MYC)
[18,19] and MYCN (n-MYC) oncogene [20]. MYCN reg-
ulates MIR17HG which itself involves in regulation of
transforming growth factor beta (TGFB) and sonic
hedgehog (SHH) pathways which have critical role in
skeletal development and limb formation [20]. Reduc-
tion of miR-17 ~ 92 expression, or that of its paralo-
gues, results in smaller embryos and postnatal death
due to hypoplastic lungs and ventricular septal defectsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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autosomal dominant Feingold syndrome 1 with variety
of abnormalities, heterozygous deletions of MIR17HG
cause Feingold syndrome 2 with only skeletal anomalies
and growth defects [20]. Three patients with germline
microdeletions of the chromosomal region 13q31.3, in-
cluding the miR-17-92 cluster and first 5 exons of the
GPC5 gene are presented with Feingold syndrome 2
[20]. In support of the hypothesis of MIR17HG having a
major role in their patients’ abnormal phenotype, de
Pontal and colleagues described two individuals with
defective GPC5 gene expression who nevertheless had a
normal phenotype [20]. Additionally, transgenic mice
hemizygous for miR-17 ~ 92 deletion (with no involve-
ment of GPC5) showed severe abnormalities in their
digits but no change in GPC5 expression [21]. This sug-
gests that GPC5 is not critical for normal skeletal devel-
opment. However, GPC5 deletion or mutations may still
contribute to certain clinical features observed in most
patients with deletions involving both MIR17HG and
GPC5 genes.
Interestingly, duplication of the miR-17 ~ 92 and GCP5
locus has also been described in patients with digit ab-
normalities. Kannu and colleagues recently reported a
germline 912-kb duplication at 13q31.3, encompassing
miR-17 ~ 92 and GPC5, in a patient presenting with a
post-axial polydactyly type A and overgrowth [22]. Here
we describe a case involving the smallest miR-17 ~ 92
microduplication reported to date. Affected family mem-
bers exhibited multiple skeletal abnormalities, including
digit and facial anomalies.Figure 1 Photographs of proband and his mother. Proband (left) and h
downward slanting palpebral fissures.Case presentation
Case report
The proband presented at 9 years of age with develop-
mental delay, autism spectrum disorder, speech delay,
attention deficit hyperactivity disorder, and a variety of
physical abnormalities: short stature (10th percentile for
the proband and <1st percentile for the mother), mild
macrocephaly in relation to body size, metacarpal and
metatarsal anomalies, flat feet, lower facial weakness,
hypertelorism, downward slanting palpebral fissures, fre-
quent dental caries, and digit anomalies including brachy-
dactyly, wide nail beds, deviation of fourth digits to the
ulnar side, radially displaced thumbs, and mild clinodac-
tyly (Figures 1 and 2). The hand breath, hand length, and
hand circumference were <1% for age and gender for both
the mother and proband. The proband was born at full
term via vaginal delivery to a G4P4A0L4 25-year-old
mother without any known maternal complications or
infections. Birth weight (3,580 grams) was normal. No
prenatal, perinatal, or postnatal complications were noted,
and he was discharged on the second day of life. He first
walked at 12 months but did not speak words until 3 years.
Interventions included speech and physical therapy, an
individualized education plan, and special education for
diagnoses of developmental delay and autism spectrum
disorder.
The proband had five half-brothers resulting from his
mother’s four different marriages (Figure 3). All were
examined except two (18 and 17 years old), who were
not available (living in Guatemala) but were reported to
exhibit developmental delay and autism. One of theis mother (right) showing lower facial weakness, hypertelorism, and
Figure 2 Radiographs showing digit anomalies of the proband. Anomalies included brachydactyly, wide nail beds, deviation of fourth digits
to the ulnar side, radial displacement of thumbs, and clinodactyly of the fourth and fifth digit tarsal.
Figure 3 Pedigree: The proband (III4) has five half-brothers (III1, III2, III3, III5 and III6) resulting from his mother’s four different
marriages. The proband (III4), his mother (II4) and one of his half-brothers (III3) harboring a 516 kb duplication at 13q13.3 (red small circle)
showed dysmorphic facial features, lower facial weakness, and relative macrocephaly (blue square) as well as digit anomalies including
clinodactyly, brachydactyly, and short stature (green square). Developmental delay (red square) and autism (Yellow Square) were observed in all
six brothers. The mother showed all of the above abnormalities except autism.
Hemmat et al. Molecular Cytogenetics 2014, 7:27 Page 3 of 6
http://www.molecularcytogenetics.org/content/7/1/27
Hemmat et al. Molecular Cytogenetics 2014, 7:27 Page 4 of 6
http://www.molecularcytogenetics.org/content/7/1/27half-brothers (11 years old) and mother showed similar
clinical features as the proband, although the mother
did not have a diagnosis of autism. The other two exam-
ined half-brothers (4 and 5 years old) had normal hand
breath, hand length, and hand circumference measure-
ments (at the 50 percentile for their ages), with no evi-
dence of polydactyly or syndactyly. However, all six
brothers had autism and developmental delay.
Methods
Genomic DNA was extracted from whole blood using the
Gentra Puregene kit (Qiagen-Sciences, Maryland, USA).
Microdeletion/microduplication screening was performed
for the proband, his mother, and available half-brothers
using an SNP-array platform (CytoScan HD; Affymetrix,
Santa Clara, CA), following the manufacturer’s instruction.
The CytoScan HD array has 2.67 million probes, including
1.9 million copy number probes and 0.75 million SNPFigure 4 Duplication of 13q31.3. A. Chromosome 13 with duplication at
weighted log2 ratio, copy number state, and the genes at the duplicated r
at chromosome 13, position 91,989,261 to 92, 504,857, including miR-17 ~probes. Array data were analyzed using the Chromosome
Analysis Suite (ChAS) (Affymetrix, Inc.) software v 2.0.
Results
This analysis detected a microduplication of 516 kb at
13q31.3 (Figure 4), which encompassed the miR-17 ~ 92
cluster genes (MIR17, MIR18A, MIR19A, MIR20A,
MIR19B1, MIR92A1) and the first five exons of the
GPC5 gene. The duplication extended from 91,989,261
to 92,504,857 to 15,433,672 bp (UCSC genome Browser;
http://genome.ucsc.edu/; hg19 release). FISH results
suggested tandem duplication and excluded an unbal-
anced translocation or insertion. The duplication was
also detected in our proband, his mother, and one of his
five half-brothers, segregating with short stature, clino-
dactyly, brachydactyly, short digits, and dysmorphic fa-
cial features with lower facial weakness. Developmental
delay and autism were observed in all six brothers and13q31.3. B. Proband SNP-array results, including the log2 ratio,
egion. C. Database of genomic variants showing 515.6 kb duplication
92 and five exons of the GCP5 gene.
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duplication, although they might have been maternally
inherited (Figure 3).
Additionally, SNP array analysis in the proband’s
mother showed a number of copy neutral regions of al-
lelic homozygosity (ROH). The additive amount of ROH
across the genome that span >5 Mb totaled approximately
128 Mb. The implications of ROH are unclear at present.
In theory, when the degree of homozygosity is signifi-
cant, there is an increased risk for recessive Mendelian
disorders.
Discussion and conclusions
Multiple studies have indicated that the gene content of
the 13q31.3 region is associated with normal growth and
skeletal development. In this respect de Pontual et al.
and colleagues [20] stated that deletion of miR-17 ~ 92
plays a major role in skeletal defects and ruled out any
involvement of the GCP5 gene. In contrast, Kannu et al.
recently reported a case with a larger microduplication
but very similar gene content to our case [22]. Their
patient had a 909-kb microduplication encompassing
the same genes, including the entire miR17 ~ 92 cluster
and first five exons of the GPC5 gene, exhibited post-
axial polydactyly type A and overgrowth. The authors
proposed that deletion of the miR-17 ~ 92 cluster genes
may result in haploinsufficiency and growth retardation,
while duplication results in overexpression and over-
growth; Van der Zwaag et al. also reported a larger (5.6
Mb) duplication, which included the MIR17HG and
GPC5 genes, in a patient with postaxial polydactyly A2
[23]. However, our case contradicts their hypothesis,
since the affected family members had a similar duplica-
tion but exhibited features of growth retardation such
as short stature, brachydactyly, and short digits. Our
finding is also supported by Shan et al. [24], who devel-
oped a line of transgenic mice overexpressing pre-
miR17 by introducing a fragment of cDNA harboring
four copies of the pre-miR-17. The transgenic mice over-
expressed miR17 and exhibited overall growth retardation,
smaller organs, and greatly reduced hematopoietic cell
lineages.
While recent reports strongly support the involvement
of miR-17 ~ 92 in skeletal development, the role of GCP5
gene has been controversial. No abnormal phenotype has
been observed in transgenic mice and two control individ-
uals harboring heterozygous deletion of GPC5 only [20],
while the expression of GPC5 gene has been well char-
acterized in the developing mouse limb bud, where it is
highly expressed in the mesenchymal condensation of
the digits [25].
This report represents the smallest microduplication
involving the MIR17HG and GPC5 genes described to
date and provide additional evidence to support thecomplex role of miR-17 ~ 92 gene dosage in normal
growth and skeletal development. The skeletal anomal-
ies observed in affected family members of our patient
appear to be inconsistent with other reported cases with
duplication. It is possible that either deletion or duplica-
tion of miR-17 ~ 92 cluster can interrupt skeletal develop-
mental pathways, with variable expression from growth
retardation to overgrowth. Further investigations, such as
expression studies, are needed to clarify the exact role of
miR-17 ~ 92 in skeletal development.
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